SIR-Spheres Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting
The scientific program includes a CME session entitled Liver-Directed Radiomicrosphere Therapy: Advances and Opportunities for Nuclear Medicine. Organized and moderated by Seza Gulec, M.D., F.A.C.S. and the Nuclear Oncology Council of SNM, the program is designed to review the techniques and clinical applications of Selective Internal Radiation Therapy (SIRT) in the management of metastatic liver cancers.
This CME symposium will discuss the scientific basis of microsphere therapy, clinical indications, patient selection, imaging protocols for disease assessment and patient follow-up, treatment planning and dosimetry. New data regarding ongoing clinical trials with SIR-Spheres microspheres will also be featured.
"Sirtex is proud to support SNM and its mission to improve cancer care and prevention and ensure that all patients with liver metastases receive the highest quality of care," says Dr. John Reddington, President of Sirtex Medical.
(1) Sirtex Medical Inc.'s SIR-Spheres microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device, that is presented in peer-reviewed literature, may differ from the approved USA indications as per the labeling for the product.
About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA approval), and the European Union (CE Mark) and additionally supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel and Turkey with more than 7,500 patients having been treated to date.
For more information, visit www.sirtex.com.
(R) SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd.
Andrea Moody, 919-457-0743
Posted: June 2008